Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy

NCT05985954 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Cetuximab
DRUG: Ulixertinib
DRUG: Encorafenib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]